Toll Free: 1-888-928-9744
Published: Jul, 2015 | Pages:
36 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
La Jolla Pharmaceutical Company - Product Pipeline Review - 2015 Summary Global Markets Direct's, 'La Jolla Pharmaceutical Company - Product Pipeline Review - 2015', provides an overview of the La Jolla Pharmaceutical Company's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of La Jolla Pharmaceutical Company's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of La Jolla Pharmaceutical Company including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of La Jolla Pharmaceutical Company's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the La Jolla Pharmaceutical Company's pipeline products Reasons to buy - Evaluate La Jolla Pharmaceutical Company's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of La Jolla Pharmaceutical Company in its therapy areas of focus - Identify new drug targets and therapeutic classes in the La Jolla Pharmaceutical Company's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of La Jolla Pharmaceutical Company and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of La Jolla Pharmaceutical Company - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Explore the dormant and discontinued projects of La Jolla Pharmaceutical Company and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 La Jolla Pharmaceutical Company Snapshot 5 La Jolla Pharmaceutical Company Overview 5 Key Information 5 Key Facts 5 La Jolla Pharmaceutical Company - Research and Development Overview 6 Key Therapeutic Areas 6 La Jolla Pharmaceutical Company - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 La Jolla Pharmaceutical Company - Pipeline Products Glance 10 La Jolla Pharmaceutical Company - Late Stage Pipeline Products 10 Phase III Products/Combination Treatment Modalities 10 La Jolla Pharmaceutical Company - Clinical Stage Pipeline Products 11 Phase I Products/Combination Treatment Modalities 11 La Jolla Pharmaceutical Company - Early Stage Pipeline Products 12 Preclinical Products/Combination Treatment Modalities 12 Discovery Products/Combination Treatment Modalities 13 La Jolla Pharmaceutical Company - Drug Profiles 14 LJPC-501 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 LJPC-0712 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 LJPC-101 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 LJPC-201 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 LJPC-30Sa 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 LJPC-30Sb 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 LJPC-401 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 LJPC-6417 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 LJPC-301 22 Product Description 22 Mechanism of Action 22 R&D Progress 22 La Jolla Pharmaceutical Company - Pipeline Analysis 23 La Jolla Pharmaceutical Company - Pipeline Products by Target 23 La Jolla Pharmaceutical Company - Pipeline Products by Route of Administration 24 La Jolla Pharmaceutical Company - Pipeline Products by Molecule Type 25 La Jolla Pharmaceutical Company - Pipeline Products by Mechanism of Action 26 La Jolla Pharmaceutical Company - Recent Pipeline Updates 27 La Jolla Pharmaceutical Company - Dormant Projects 29 La Jolla Pharmaceutical Company - Discontinued Pipeline Products 30 Discontinued Pipeline Product Profiles 30 GCS-100 30 LJPC-1010 30 La Jolla Pharmaceutical Company - Company Statement 31 La Jolla Pharmaceutical Company - Locations And Subsidiaries 34 Head Office 34 Other Locations & Subsidiaries 34 Appendix 35 Methodology 35 Coverage 35 Secondary Research 35 Primary Research 35 Expert Panel Validation 35 Contact Us 35 Disclaimer 36
List of Tables
La Jolla Pharmaceutical Company, Key Information 5 La Jolla Pharmaceutical Company, Key Facts 5 La Jolla Pharmaceutical Company - Pipeline by Indication, 2015 7 La Jolla Pharmaceutical Company - Pipeline by Stage of Development, 2015 8 La Jolla Pharmaceutical Company - Monotherapy Products in Pipeline, 2015 9 La Jolla Pharmaceutical Company - Phase III, 2015 10 La Jolla Pharmaceutical Company - Phase I, 2015 11 La Jolla Pharmaceutical Company - Preclinical, 2015 12 La Jolla Pharmaceutical Company - Discovery, 2015 13 La Jolla Pharmaceutical Company - Pipeline by Target, 2015 23 La Jolla Pharmaceutical Company - Pipeline by Route of Administration, 2015 24 La Jolla Pharmaceutical Company - Pipeline by Molecule Type, 2015 25 La Jolla Pharmaceutical Company - Pipeline Products by Mechanism of Action, 2015 26 La Jolla Pharmaceutical Company - Recent Pipeline Updates, 2015 27 La Jolla Pharmaceutical Company - Dormant Developmental Projects,2015 29 La Jolla Pharmaceutical Company - Discontinued Pipeline Products, 2015 30 La Jolla Pharmaceutical Company, Subsidiaries 34
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.